Cargando…
Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017207/ https://www.ncbi.nlm.nih.gov/pubmed/31861415 http://dx.doi.org/10.3390/cancers12010008 |
_version_ | 1783497149847175168 |
---|---|
author | Chung, Doo Yong Kang, Dong Hyuk Kim, Jong Won Kim, Do Kyung Lee, Joo Yong Hong, Chang Hee Cho, Kang Su |
author_facet | Chung, Doo Yong Kang, Dong Hyuk Kim, Jong Won Kim, Do Kyung Lee, Joo Yong Hong, Chang Hee Cho, Kang Su |
author_sort | Chung, Doo Yong |
collection | PubMed |
description | Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested. Therefore, we conducted a meta-analysis to compare oncologic outcomes between the treatment sequences of ABI-ENZA and ENZA-ABI in patients with mCRPC. The primary endpoint was a combined progression-free survival (PFS), and the secondary endpoint was overall survival (OS). A total of five trials on 553 patients were included in this study. Each of the included studies was retrospective. In two studies including both chemo-naïve and post-chemotherapy mCRPC patients, for ABI-ENZA compared with ENZA-ABI, pooled hazard ratios (HRs) for PFS and OS were 0.37 (p < 0.0001; 95% confidence intervals (CIs), 0.23–0.60) and 0.64 (p = 0.10; 95% CIs, 0.37–1.10), respectively. In three studies with chemo-naïve mCRPC patients only, for ABI-ENZA compared with ENZA-ABI, pooled HRs for PFS and OS were 0.57 (p = 0.02; 95% CIs, 0.35–0.92) and 0.86 (p = 0.39; 95% CIs, 0.61–1.21), respectively. The current meta-analysis revealed that ABI-ENZA had a significantly more favorable oncological outcome, but the level of evidence was low. Therefore, large-scale randomized trials may be needed. |
format | Online Article Text |
id | pubmed-7017207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70172072020-02-28 Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis Chung, Doo Yong Kang, Dong Hyuk Kim, Jong Won Kim, Do Kyung Lee, Joo Yong Hong, Chang Hee Cho, Kang Su Cancers (Basel) Article Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested. Therefore, we conducted a meta-analysis to compare oncologic outcomes between the treatment sequences of ABI-ENZA and ENZA-ABI in patients with mCRPC. The primary endpoint was a combined progression-free survival (PFS), and the secondary endpoint was overall survival (OS). A total of five trials on 553 patients were included in this study. Each of the included studies was retrospective. In two studies including both chemo-naïve and post-chemotherapy mCRPC patients, for ABI-ENZA compared with ENZA-ABI, pooled hazard ratios (HRs) for PFS and OS were 0.37 (p < 0.0001; 95% confidence intervals (CIs), 0.23–0.60) and 0.64 (p = 0.10; 95% CIs, 0.37–1.10), respectively. In three studies with chemo-naïve mCRPC patients only, for ABI-ENZA compared with ENZA-ABI, pooled HRs for PFS and OS were 0.57 (p = 0.02; 95% CIs, 0.35–0.92) and 0.86 (p = 0.39; 95% CIs, 0.61–1.21), respectively. The current meta-analysis revealed that ABI-ENZA had a significantly more favorable oncological outcome, but the level of evidence was low. Therefore, large-scale randomized trials may be needed. MDPI 2019-12-18 /pmc/articles/PMC7017207/ /pubmed/31861415 http://dx.doi.org/10.3390/cancers12010008 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chung, Doo Yong Kang, Dong Hyuk Kim, Jong Won Kim, Do Kyung Lee, Joo Yong Hong, Chang Hee Cho, Kang Su Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title | Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_full | Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_fullStr | Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_short | Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_sort | comparison of oncologic outcomes between two alternative sequences with abiraterone acetate and enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017207/ https://www.ncbi.nlm.nih.gov/pubmed/31861415 http://dx.doi.org/10.3390/cancers12010008 |
work_keys_str_mv | AT chungdooyong comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT kangdonghyuk comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT kimjongwon comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT kimdokyung comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT leejooyong comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT hongchanghee comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT chokangsu comparisonofoncologicoutcomesbetweentwoalternativesequenceswithabirateroneacetateandenzalutamideinpatientswithmetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis |